Our World in Data

News and Video Search Results

News coverage

TALVEY®▼ (talquetamab) demonstrated highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma

GlobeNewswire 14 Jun 2024

24-month overall survival rate of 67 percent achieved with talquetamab 0.8mg/kg biweekly dosing in the Phase 1/2 MonumenTAL-1..

Analysis of the Global Marine Propulsion Engines Market, 2024-2030, Featuring Profiles of 44 Major Players Including Caterpillar, Cummins, Hyundai Heavy Industries, Scania, and Wartsila
GlobeNewswire 14 Jun 2024
Ethylene Tetrafluoroethylene (ETFE) Global Market Report 2024-2030, Featuring Profiles of Leading Players 3M Company, Asahi Glass Co, and Daikin Industries - A $580.3 Million Market Opportunity
GlobeNewswire 14 Jun 2024
$97.8 Billion Social Media Management Market Forecast Report, 2030: Uncover the Most Lucrative Segments, Emerging Trends, and Major Player Prospects
GlobeNewswire 14 Jun 2024
Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax as first-line treatment for patients with chronic lymphocytic leukaemia, including those with high-risk disease
GlobeNewswire 14 Jun 2024

0 shares 1 views

You might like

Our World in Data media coverage

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

GlobeNewswire 14 Jun 2024

All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel)..

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
GlobeNewswire 14 Jun 2024
Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up
GlobeNewswire 14 Jun 2024
Signify publishes comparable financials for 2023 and Q1 2024 following implementation of new organizational structure
GlobeNewswire 14 Jun 2024
Dun & Bradstreet and HSBC team up to support Hong Kong businesses embark on their ESG journeys
PR Newswire Asia 14 Jun 2024

Advertisement

More coverage

Xtend Unveils Powerful AI-Driven Products to Supercharge Marketing Conversions

PR Newswire Asia 14 Jun 2024

SINGAPORE, June 14, 2024 /PRNewswire/ -- Xtend, a leading AI-powered marketing and analytics company, announced the launch of a..

Safari Tourism Market Size to Surpass US$ 56.57 Billion by 2033, The Brainy Insights
GlobeNewswire 14 Jun 2024
TE Connectivity (TE) Showcases Advanced IoT Products at CommunicAsia 2024
PR Newswire Asia 14 Jun 2024
Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the 2024 ESMO Virtual Plenary
PR Newswire Asia 14 Jun 2024
Arm Holdings plc to Join the Nasdaq-100 Index® Beginning June 24, 2024
GlobeNewswire 14 Jun 2024